Infection Risk and Prevention

Infection is a major source of morbidity and mortality in inflammatory rheumatic disease, reflecting both immune dysregulation from the disease itself and the immunosuppressive effect of treatment. Recognising heightened risk, screening for latent infections before therapy, and vaccination are central to how the field manages this trade-off. This topic surveys infection risk and its prevention as a systemic dimension of rheumatic disease.

Definition

Infection risk in rheumatic disease is the increased susceptibility to common, opportunistic, and reactivation infections arising from immune dysregulation and immunosuppressive therapy, together with the preventive strategies (screening and vaccination) used to mitigate it.

Scope

The entry covers the determinants of infection risk in rheumatic disease (disease activity, glucocorticoids, conventional and biologic immunosuppressants), the specific concern of reactivation infections such as tuberculosis with tumour-necrosis-factor inhibitors, and the principles of vaccination and pre-treatment screening. It is a reference overview and does not provide screening schedules, dosing, or individual prophylaxis recommendations.

Core questions

• What makes patients with inflammatory rheumatic disease more susceptible to infection?
• How do different immunomodulatory therapies alter the spectrum of infection risk?
• What roles do pre-treatment screening and vaccination play in prevention?

Key concepts

• Disease- versus treatment-related immunosuppression
• Opportunistic and reactivation infections
• Latent tuberculosis reactivation with TNF inhibitors
• Hepatitis B reactivation
• Vaccination in immunosuppressed patients
• Live-vaccine considerations under immunosuppression

Mechanisms

Active inflammatory disease, glucocorticoids, and conventional and targeted immunosuppressants each impair host defence in distinct ways, shifting susceptibility toward common bacterial, opportunistic, and reactivation infections. Tumour-necrosis-factor inhibition, for example, compromises granuloma maintenance and is associated with reactivation of latent tuberculosis, which is why screening before such therapy became standard. Vaccination aims to restore protection where possible, while the response to vaccines and the safety of live vaccines depend on the degree and type of immunosuppression.

Clinical relevance

Balancing disease control against infection risk is a defining consideration in the use of immunomodulatory therapy, which is why screening and vaccination are integral to how rheumatic diseases are studied and managed at the population level. This entry describes those principles for reference and does not provide screening intervals, drug-specific protocols, or individual prophylaxis advice.

Epidemiology

Serious infections are a leading cause of hospitalisation and excess mortality across immunosuppressed rheumatic populations, with risk influenced by disease activity, glucocorticoid exposure, and the specific immunosuppressant. The recognition that tumour-necrosis-factor inhibitors were associated with tuberculosis reactivation was an early and influential signal in this literature.

Evidence & guidelines

European League Against Rheumatism recommendations on vaccination in adult patients with autoimmune inflammatory rheumatic diseases summarise consensus on prevention, and pharmacovigilance reports such as the tuberculosis-infliximab association shaped pre-treatment screening practice. These are cited as reference points on how the field frames infection prevention, not as directives for any individual.

History

The early association between infliximab and tuberculosis reactivation, reported through pharmacovigilance, alerted the field to reactivation risk with biologic therapy and led to routine latent-tuberculosis screening before such treatment. In parallel, vaccination in immunosuppressed rheumatic patients was systematised through successive European League Against Rheumatism recommendations.

Debates

How should live vaccines be handled under immunosuppression?

The safety and timing of live vaccines in patients receiving immunosuppressive or biologic therapy remain a nuanced question that vaccination recommendations address with caution, balancing infection prevention against theoretical risks.

Seminal works

• keane-2001
• vanassen-2011
• furer-2020

Frequently asked questions

Why are patients with rheumatic disease at higher risk of infection?

Both the disease's immune dysregulation and the immunosuppressive therapies used to control it impair host defence, increasing susceptibility to common, opportunistic, and reactivation infections.

Why is tuberculosis screening done before starting some biologics?

Tumour-necrosis-factor inhibitors are associated with reactivation of latent tuberculosis, so screening for latent infection before starting such therapy became standard practice after this risk was recognised.